Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Experience with community-based amphotericin B infusion therapy.

Preeti N Malani1, Daryl D Depestel, James Riddell

  • 1Division of Infectious Diseases, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, 48109, USA.

Pharmacotherapy
|May 19, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advancing Pharmacoequity in Asthma.

JAMA·2026
Same author

Liver Necrosis in a Patient Receiving Isavuconazole: Making the Case for Therapeutic Drug Monitoring.

Open forum infectious diseases·2026
Same author

Fungal diagnostic stewardship in immunocompromised populations: a focus on molds and dimorphic fungi.

Clinical microbiology reviews·2026
Same author

AI Use in Research and the Need for Continued Guidance.

JAMA·2026
Same author

Fever, Rash, and Dizziness in a 32-Year-Old.

JAMA·2026
Same author

Driving after cannabis consumption among US adults ages 50 years and older: A short communication.

Drug and alcohol dependence·2025

Community-based amphotericin B infusion therapy is linked to significant adverse events, including nephrotoxicity and infusion reactions. A monitoring system based on IDSA guidelines effectively detected and managed these events in patients.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Nephrology

Background:

  • Community-based infusion therapy is increasingly utilized for various infections.
  • Amphotericin B, a potent antifungal agent, is associated with a spectrum of adverse events.
  • Effective monitoring is crucial for managing patients receiving amphotericin B therapy outside of traditional hospital settings.

Purpose of the Study:

  • To determine the types and incidence of adverse events during community-based amphotericin B infusion therapy.
  • To evaluate the efficacy of a monitoring system, aligned with Infectious Diseases Society of America (IDSA) guidelines, in detecting and managing these adverse events.

Main Methods:

  • Retrospective review of medical records.
  • Analysis of 105 patients receiving amphotericin B from a home care provider between 1997 and 2002.

Related Experiment Videos

  • Categorization of adverse events including nephrotoxicity, electrolyte abnormalities, and infusion reactions.

    • Main Results:

    • Nephrotoxicity (41%) and electrolyte abnormalities (35%) were the most frequent adverse events.
    • Venous access device complications (11%) and infusion reactions (12%) were also observed.
    • Patients aged 60 or older, solid organ transplant recipients, and those on cyclosporine were at higher risk for nephrotoxicity.

    Conclusions:

    • Community-based amphotericin B infusion therapy is associated with a substantial rate of adverse events.
    • The IDSA-guided monitoring system proved effective in identifying and managing these adverse events.
    • Regular monitoring of renal function and electrolytes is essential for patient safety during home-based amphotericin B treatment.